Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ovid Therapeutics Inc.    OVID

OVID THERAPEUTICS INC.

(OVID)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/17/2020 11/18/2020 11/19/2020 11/20/2020 11/23/2020 Date
6.05(c) 6.01(c) 6.11(c) 6.14(c) 6.12(c) Last
558 192 498 723 410 061 385 572 522 501 Volume
+0.83% -0.66% +1.66% +0.49% -0.33% Change
More quotes
Financials (USD)
Sales 2020 6,85 M - -
Net income 2020 -81,5 M - -
Net Debt 2020 - - -
P/E ratio 2020 -4,48x
Yield 2020 -
Sales 2021 8,64 M - -
Net income 2021 -94,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,99x
Yield 2021 -
Capitalization 388 M 388 M -
Capi. / Sales 2020 56,7x
Capi. / Sales 2021 44,9x
Nbr of Employees 65
Free-Float 65,3%
More Financials
Company
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to... 
More about the company
Notations Surperformance© of Ovid Therapeutics Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about OVID THERAPEUTICS INC.
11/23OVID THERAPEUTICS : to Present at the American Epilepsy Society (AES) 2020 Virtu..
AQ
11/23Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Vir..
GL
11/13OVID THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Provides Co..
AQ
11/13OVID THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
11/12OVID THERAPEUTICS INC. : Results of Operations and Financial Condition, Financia..
AQ
11/12OVID THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Provides Co..
AQ
11/12Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides C..
GL
10/22OVID THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
10/15OVID THERAPEUTICS : to Host Educational Webinar on Angelman Syndrome and OV101 D..
AQ
10/14OVID THERAPEUTICS : to Host Educational Webinar on Angelman Syndrome and OV101 D..
AQ
10/14Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 ..
GL
10/13OVID THERAPEUTICS : to Present at the Child Neurology Society International Chil..
AQ
10/12OVID THERAPEUTICS : Thinking about buying stock in DouYu, Adamis Pharmaceuticals..
PR
10/12OVID THERAPEUTICS : to Present at the Child Neurology Society/International Chil..
AQ
10/12Ovid Therapeutics to Present at the Child Neurology Society/International Chi..
GL
More news
News in other languages on OVID THERAPEUTICS INC.

- No features available -

More news
Chart OVID THERAPEUTICS INC.
Duration : Period :
Ovid Therapeutics Inc. Technical Analysis Chart | OVID | US6904691010 | MarketScreener
Technical analysis trends OVID THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 14,67 $
Last Close Price 6,12 $
Spread / Highest target 243%
Spread / Average Target 140%
Spread / Lowest Target 63,4%
EPS Revisions
Managers
NameTitle
Jeremy Max Levin Chairman & Chief Executive Officer
Amit Rakhit President & Chief Medical Officer
Jeffrey A. Rona Chief Financial Officer
Karen Bernstein Independent Director
Bart Friedman Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
OVID THERAPEUTICS INC.47.47%388
GILEAD SCIENCES, INC.-7.83%75 074
VERTEX PHARMACEUTICALS-0.49%56 654
REGENERON PHARMACEUTICALS39.45%55 264
WUXI APPTEC CO., LTD.63.37%39 757
BIONTECH SE214.34%25 644